Unveiling Histiocytic Sarcoma: A Rare Case of Diagnostic Complexity and Therapeutic Resistance

Histiocytic sarcoma (HS) is a rare and aggressive hematological malignancy. It is derived from the lineage of macrophages or monocytes. HS commonly presents as a mass in areas such as the gastrointestinal tract and soft tissues. This case highlights the clinical challenges in diagnosing and managing HS in a 37-year-old female patient. Accurate diagnosis relies on immunohistochemistry and molecular studies, while treatment outcomes remain suboptimal. The patient underwent multimodal therapies, including chemotherapy, targeted therapy, and radiation therapy, with disease progression observed despite treatment. This report underscores the need for novel approaches to improve outcomes in HS and the role of ARID2 mutations, which in our case limits the applicability of immune checkpoint inhibitors in disease management.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-03-20
DOI
https://doi.org/10.7759/cureus.80927
Primary Topic
Histiocytic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unveiling Histiocytic Sarcoma: A Rare Case of Diagnostic Complexity and Therapeutic Resistance

Syed Abbas Raza, Muhammad Asim Khan, Abid Nawaz Khan Adil, Bakht Rehman
Cureus
Histiocytic Disorders and Treatments
article

Unveiling Histiocytic Sarcoma: A Rare Case of Diagnostic Complexity and Therapeutic Resistance

Syed Abbas Raza, Muhammad Asim Khan, Abid Nawaz Khan Adil, Bakht Rehman
article en

Abstract

Histiocytic sarcoma (HS) is a rare and aggressive hematological malignancy. It is derived from the lineage of macrophages or monocytes. HS commonly presents as a mass in areas such as the gastrointestinal tract and soft tissues. This case highlights the clinical challenges in diagnosing and managing HS in a 37-year-old female patient. Accurate diagnosis relies on immunohistochemistry and molecular studies, while treatment outcomes remain suboptimal. The patient underwent multimodal therapies, including chemotherapy, targeted therapy, and radiation therapy, with disease progression observed despite treatment. This report underscores the need for novel approaches to improve outcomes in HS and the role of ARID2 mutations, which in our case limits the applicability of immune checkpoint inhibitors in disease management.

CureusVol. 17(3)
University of Kansas Medical Center (US)
Openalex Percentile: Top 93%
Histiocytic Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.